
  
    
      
        Background_NNP
        With_IN one_CD million_CD new_JJ cases_NNS each_DT year_NN ,_, breast_NN cancer_NN is_VBZ
        the_DT most_RBS common_JJ cancer_NN among_IN women_NNS and_CC is_VBZ the_DT leading_VBG cause_NN
        of_IN death_NN in_IN women_NNS 30_CD to_TO 70_CD years_NNS of_IN age_NN in_IN the_DT world_NN ._.
        Breast_NNP cancer_NN results_NNS from_IN genetic_JJ and_CC environmental_JJ
        factors_NNS including_VBG diet_NN ,_, radiation_NN and_CC hormones_NNS [_NN 1_CD 2_CD 3_CD 4_CD 5_CD
        ]_NN ._. The_DT molecular_JJ events_NNS involved_VBN in_IN breast_NN carcinogenesis_NNS ,_,
        however_RB ,_, remain_VB to_TO be_VB elucidated_JJ ._.
        Numerous_JJ studies_NNS have_VBP shown_VBN that_DT polypeptide_NN growth_NN
        factors_NNS such_JJ as_IN insulin-like_JJ growth_NN factors_NNS (_( IGFs_NNP )_) are_VBP
        mitogens_NNS for_IN breast_NN cancer_NN cells_NNS [_NN 6_CD 7_CD 8_CD 9_CD ]_NN ._. The_DT IGF-I_NNP
        and_CC IGF-II_NNP signal_NN through_IN a_DT common_JJ tyrosine_NN kinase_NN
        receptor_NN ,_, the_DT insulin-like_JJ growth_NN factor_NN 1_CD receptor_NN
        (_( IGF_NNP 1_CD R_NN )_) ,_, and_CC have_VBP mitogenic_JJ and_CC cell_NN survival_NN actions_NNS that_WDT
        may_MD promote_VB tumor_NN development_NN ._. Modulation_NNP of_IN this_DT mitogenic_JJ
        pathway_NN occurs_VBZ in_IN part_NN via_IN the_DT M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN ,_, which_WDT functions_NNS
        in_IN the_DT internalization_NN and_CC degradation_NN of_IN IGF-II_NNP [_NN 10_CD ]_NN ._.
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN is_VBZ also_RB important_JJ in_IN activation_NN of_IN TGF-β_NNP ,_, a_DT
        potent_JJ growth_NN inhibitor_NN for_IN most_JJS cell_NN types_NNS ,_, and_CC in_IN
        binding_JJ ,_, transport_NN and_CC activation_NN of_IN lysosomal_NN enzymes_NNS ,_,
        such_JJ as_IN cathepsins_NNS [_NN 12_CD 13_CD ]_NN ._. It_PRP has_VBZ been_VBN shown_VBN that_IN
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN expression_NN is_VBZ significantly_RB reduced_VBN in_IN both_DT rat_NN
        and_CC human_JJ hepatocellular_NN carcinomas_NNS [_NN 14_CD ]_NN ._. Loss_NN of_IN
        hetorozygosity_NN (_( LOH_NNP )_) at_IN the_DT M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD receptor_NN gene_NN locus_JJ on_IN
        6_CD q_NN 26_CD -_: 27_CD coupled_VBN with_IN somatic_JJ point_NN mutations_NNS in_IN the_DT
        remaining_VBG allele_NN has_VBZ recently_RB been_VBN demonstrated_VBN in_IN liver_NN
        and_CC breast_NN cancers_NNS [_NN 15_CD 16_CD 17_CD 18_CD 19_CD 20_CD 21_CD 22_CD 23_CD ]_NN ._. In_IN
        addition_NN ,_, somatic_JJ mutations_NNS of_IN the_DT M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN gene_NN were_VBD also_RB
        found_VBN in_IN prostate_NN cancer_NN ,_, lung_NN carcinoma_NN ,_, and_CC genetically_RB
        unstable_JJ cancers_NNS of_IN the_DT endometrium_NN ,_, brain_NN ,_, stomach_NN and_CC
        colorectum_NN [_NN 24_CD 25_CD 26_CD 27_CD 28_CD 29_CD ]_NN ._. The_DT findings_NNS of_IN LOH_NNP and_CC
        mutations_NNS of_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN in_IN a_DT wide_JJ variety_NN of_IN tumor_NN types_NNS
        have_VBP led_VBN to_TO the_DT proposition_NN that_IN the_DT M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN is_VBZ a_DT tumor_NN
        suppressor_NN gene_NN ._. In_IN addition_NN to_TO genetic_JJ data_NNS ,_, a_DT tumor_NN
        suppressor_NN gene_NN candidate_NN has_VBZ to_TO meet_VB functional_JJ criteria_NNS ._.
        The_DT functional_JJ characteristics_NNS of_IN a_DT tumor_NN suppressor_NN gene_NN
        have_VBP not_RB been_VBN well_RB established_VBN for_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN ._. Thus_RB ,_, further_JJ
        studies_NNS that_WDT address_VBP the_DT relationship_NN between_IN the_DT
        functional_JJ M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN level_NN and_CC cell_NN growth_NN activity_NN are_VBP
        needed_VBN ._.
        To_TO verify_VB whether_IN decreased_VBD levels_NNS of_IN functional_JJ
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN can_MD provide_VB a_DT growth_NN advantage_NN for_IN cancer_NN cells_NNS ,_,
        we_PRP used_VBD viral_JJ and_CC ribozyme_NN strategies_NNS to_TO reduce_VB the_DT
        expression_NN of_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN in_IN human_JJ breast_NN cancer_NN cells_NNS and_CC
        then_RB examined_VBD the_DT effect_NN on_IN growth_NN and_CC apoptosis_NNS of_IN these_DT
        cells_NNS ._.
      
      
        Methods_NNP
        
          Construction_NNP of_IN a_DT recombinant_JJ adenoviral_NN vector_NN
          containing_VBG the_DT M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R-_NNP ribozyme_NN
          A_DT 49_CD bp_NN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN ribozyme_NN oligonucleotide_NN ,_,
          5_CD '_POS -_: GAATTCTCCACACTGATGAGCCGCTTCGGCGGCGAAACATTCAACGCGT-_NNP 3_CD '_POS
          and_CC the_DT corresponding_JJ reverse_NN complementary_JJ strand_NN were_VBD
          synthesized_JJ ._. The_DT fragments_NNS were_VBD subcloned_JJ into_IN pRz_NN 951_CD to_TO
          produce_VB a_DT plasmid_NN (_( designated_VBN as_IN pRz-IGF_JJ 2_CD R_NN )_) containing_VBG a_DT
          ribozyme_NN targeted_VBN against_IN the_DT M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN ._. For_IN construction_NN
          of_IN the_DT recombinant_JJ adenovirus_JJ containing_VBG the_DT
          M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R-_NNP ribozyme_NN (_( pAd-GFP_JJ /_NN Rz-_NNP IGF_NNP 2_CD R_NN )_) ,_, the_DT segments_NNS
          containing_VBG the_DT ribozymes_NNS were_VBD amplified_VBN by_IN PCR_NNP and_CC cloned_VBN
          into_IN a_DT pAdTrack-CMV_JJ vector_NN and_CC then_RB recombined_JJ
          homologously_RB with_IN an_DT adenoviral_NN backbone_NN pAdEasy_NN 1_CD vector_NN
          to_TO generate_VB pAd-GFP_JJ /_NN Rz-_NNP IGF_NNP 2_CD R_NN ,_, following_VBG the_DT protocol_NN
          described_VBN by_IN He_PRP et_CC al_NN [_NN 30_CD ]_NN ._. The_DT pAd-GFP_JJ /_NN Rz-_NNP IGF_NNP 2_CD R_NN
          carries_VBZ both_DT the_DT Rz-_NNP IGF_NNP 2_CD R_NN and_CC GFP_NNP (_( as_IN reporter_NN )_) genes_NNS ,_,
          each_DT under_IN the_DT control_NN of_IN separate_JJ cytomegalovirus_JJ (_( CMV_NNP )_)
          promoters_NNS ._. Another_DT viral_JJ vector_NN ,_, pAd-GFP_JJ ,_, which_WDT carries_VBZ
          the_DT GFP_NNP gene_NN only_RB under_IN the_DT control_NN of_IN the_DT CMV_NNP promoter_NN ,_,
          was_VBD generated_VBN and_CC used_VBN as_IN a_DT control_NN vector_NN ._. The_DT
          adenoviral_NN vector_NN DNA_NNP were_VBD linerized_JJ with_IN Pac_NNP I_PRP and_CC
          transfected_JJ into_IN the_DT replication-permissive_JJ 293_CD cells_NNS
          (_( E_NNP 1_CD A_DT transcomplementing_VBG cell_NN line_NN )_) using_VBG Lipofectamine_NNP
          (_( Life_NNP Technologies_NNPS )_) to_TO produce_VB E_NNP 1_CD -_: deleted_VBN ,_,
          replication-defective_JJ recombinant_JJ adenovirus_JJ as_IN described_VBN
          previously_RB [_NN 30_CD ]_NN ._. Large-scale_NNP amplification_NN of_IN the_DT
          recombinant_JJ adenovirus_JJ in_IN 293_CD cells_NNS was_VBD followed_VBN by_IN
          purification_NN using_VBG a_DT discontinuous_JJ CsCl_NNP gradient_NN ._. The_DT
          constructs_NNS were_VBD confirmed_VBN by_IN enzymatic_JJ digestion_NN and_CC DNA_NNP
          sequencing_VBG ._.
        
        
          Transcription_NNP and_CC cleavage_NN reaction_NN of_IN the_DT ribozyme_NN
          in_IN vitro_NN
          Plasmids_NNP containing_VBG the_DT ribozyme_NN or_CC the_DT substrate_NN
          (_( either_CC 45_CD bp_NN of_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN mRNA_NN or_CC an_DT unmatched_JJ sequence_NN
          5_CD '_POS -_: ATATTGTCCAGTGC-_NNP 3_CD '_POS )_) were_VBD linearized_JJ with_IN Mlu_NNP I_PRP ._. All_DT
          transcripts_NNS were_VBD generated_VBN with_IN T_NN 7_CD RNA_NNP polymerase_NN
          (_( Promega_NNP )_) ._. Substrate_NNP transcripts_NNS were_VBD labeled_VBN by_IN
          incorporation_NN of_IN [_NN 32_CD P_NN ]_NN UTP_NNP (_( 10_CD μCi_NN /_NN ml_NN ;_: Nen_NNP Life_NNP Science_NNP
          Products_NNPS ,_, Inc_NNP ._. )_) ._. Specific_JJ activity_NN of_IN the_DT [_NN 32_CD P_NN ]_NN UTP_NNP and_CC
          the_DT base_NN composition_NN of_IN each_DT substrate_NN molecule_NN were_VBD used_VBN
          to_TO calculate_VB substrate_NN concentration_NN ._. Ribozyme_NNP
          transcripts_NNS were_VBD quantified_VBN spectrophotometrically_RB ._.
          Cleavage_NNP reactions_NNS contained_VBD 30_CD nM_NN substrate_NN RNA_NNP ,_,
          increasing_VBG amounts_NNS (_( 60_CD nM_NN )_) of_IN ribozyme_NN ,_, 20_CD mM_NN MgCl_NNP 
          2_CD and_CC 20_CD mM_NN Tris-_NNP HCl_NNP (_( pH_NN 8_CD ._. 0_CD )_) ,_, 1_CD μl_NN
          DTT_NNP ,_, and_CC 1_CD μl_NN RNA_NNP inhibitor_NN in_IN a_DT final_JJ volume_NN of_IN 10_CD μl_NN ._.
          Cleavage_NNP reactions_NNS were_VBD incubated_JJ at_IN 37_CD °_NN C_NNP for_IN 2_CD hrs_NNS ._.
          Reactions_NNP were_VBD stopped_VBN by_IN addition_NN of_IN loading_NN buffer_NN :_: 80_CD %_NN
          formamide_NN ,_, 10_CD mM_NN Na_NNP 
          2_CD EDTA_NNP (_( pH_NN 8_CD ._. 0_CD )_) ,_, and_CC 1_CD mg_NN /_NN ml_NN each_DT
          bromophenol_NN blue_NN and_CC xylene_NN cyanol_NN ._. Cleavage_NNP products_NNS
          were_VBD analyzed_VBN on_IN 15_CD %_NN polyacrylamide_NN and_CC 8_CD M_NNP urea_NN
          denaturing_VBG gels_NNS ._. NIH_NNP Imager_NNP was_VBD used_VBN to_TO quantitate_NN
          product_NN and_CC substrate_NN fragments_NNS ._.
        
        
          Cell_NNP cultures_NNS and_CC infection_NN with_IN Ad-_NNP GFP_NNP /_NN IGF_NNP 2_CD R-R_NNP z_SYM
          and_CC Ad-_NNP GFP_NNP
          MCF-_NNP 7_CD cells_NNS were_VBD cultured_JJ in_IN DMEM_NNP medium_NN containing_VBG
          10_CD %_NN FBS_NNP at_IN 37_CD °_NN C_NNP in_IN a_DT tissue_NN culture_NN incubator_NN with_IN 5_CD %_NN CO_NNP 
          2_CD and_CC 98_CD %_NN relative_JJ humidity_NN ._. Cells_NNP
          were_VBD used_VBN for_IN experiments_NNS after_IN 2_CD -_: 3_CD days_NNS in_IN culture_NN ._.
          Viral_NNP infections_NNS were_VBD carried_VBN out_IN by_IN adding_VBG viral_JJ
          particles_NNS at_IN various_JJ concentrations_NNS (_( usually_RB ,_, 2_CD ×_NN 10_CD
          8_CD virus_NN particles_NNS /_NN ml_NN )_) to_TO culture_NN medium_NN containing_VBG 2_CD %_NN FBS_NNP ._.
          Initially_RB ,_, optimal_NN viral_JJ concentration_NN was_VBD determined_VBN by_IN
          using_VBG Ad-_NNP GFP_NNP to_TO achieve_VB an_DT optimal_NN balance_NN of_IN high_JJ gene_NN
          expression_NN and_CC low_JJ viral_JJ titer_NN to_TO minimize_VB cytotoxicity_NN ._.
          After_IN 24_CD hrs_NNS of_IN incubation_NN ,_, the_DT infection_NN medium_NN was_VBD
          replaced_VBN with_IN normal_JJ (_( 10_CD %_NN FBS_NNP )_) culture_NN medium_NN ._. For_IN
          treatment_NN with_IN IGF-II_NNP ,_, cells_NNS were_VBD incubated_JJ with_IN 50_CD ng_NN /_NN ml_NN
          IGF-II_NNP after_IN infection_NN with_IN Ad-_NNP GFP_NNP /_NN IGF_NNP 2_CD R-R_NNP z_SYM or_CC Ad-_NNP GFP_NNP ._.
          Seventy_CD two_CD hrs_NNS post_NN infection_NN ,_, cells_NNS were_VBD used_VBN for_IN
          analysis_NN of_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN gene_NN expression_NN and_CC its_PRP$ effect_NN on_IN
          cell_NN growth_NN ._.
        
        
          Analysis_NNP of_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN gene_NN expression_NN in_IN MCF-_NNP 7_CD
          cells_NNS
          The_DT M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN transcripts_NNS were_VBD determined_VBN by_IN RT-PCR_NNP
          using_VBG the_DT GeneAmp_NNP EZ_NNP rTt_NN RNA_NNP PCR_NNP kit_NN (_( Roche_NNP )_) ._. Total_NNP RNA_NNP
          was_VBD extracted_VBN from_IN cultured_JJ cells_NNS using_VBG an_DT RNA_NNP isolation_NN
          kit_NN (_( Qiagen_NNP )_) ,_, according_VBG to_TO the_DT manufacturer_NN 's_POS protocol_NN ._.
          M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN transcripts_NNS were_VBD amplified_VBN using_VBG primers_NNS
          5_CD '_POS -_: GACAGGCTTGTCCTGAGTTA-_NNP 3_CD '_POS and_CC 5_CD '_POS -_: TTCTGCTCTGGTTCTGCATG_NNP
          3_CD '_POS ,_, specific_JJ to_TO the_DT M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN receptor_NN ._. Each_DT RT-PCR_NNP assay_NN
          was_VBD performed_VBN in_IN triplicate_NN ._. Primers_NNP specific_JJ for_IN human_JJ
          β-actin_JJ cDNA_NN were_VBD added_VBN to_TO a_DT parallel_JJ reaction_NN to_TO
          standardize_VB for_IN variations_NNS in_IN PCR_NNP between_IN samples_NNS ._. PCR_NNP
          products_NNS were_VBD resolved_VBN on_IN a_DT 1_CD ._. 0_CD %_NN agarose_NN gel_NN ,_, visualized_JJ
          under_IN UV_NNP light_JJ and_CC quantitated_JJ using_VBG NIH_NNP Imager_NNP ._.
        
        
          Measurement_NNP of_IN 125_CD I_PRP -_: IGF-II_NNP internalization_NN
          Cells_NNP were_VBD incubated_JJ at_IN 37_CD °_NN C_NNP for_IN 2_CD hrs_NNS in_IN serum-free_JJ
          DMEM_NNP containing_VBG 125_CD I-_NNP labeled_VBD IGF-II_NNP (_( 0_CD ._. 5_LS ng_NN /_NN ml_NN )_) with_IN or_CC
          without_IN excess_JJ unlabeled_JJ IGF-II_NNP (_( 2_CD μg_NN /_NN ml_NN )_) ._. Following_VBG the_DT
          incubation_NN ,_, the_DT cells_NNS were_VBD washed_VBN three_CD times_NNS with_IN
          ice-cold_JJ PBS_NNP ,_, and_CC cell-associated_JJ radioactivity_NN was_VBD
          determined_VBN by_IN a_DT γ-counter_JJ ._. Specific_JJ internalized_JJ
          125_CD I-IGF-II_NNP was_VBD calculated_VBN by_IN subtracting_VBG the_DT counts_NNS of_IN
          samples_NNS with_IN excessive_JJ unlabeled_JJ IGF-II_NNP from_IN that_DT without_IN
          unlabeled_JJ IGF-II_NNP ,_, and_CC normalized_JJ to_TO protein_NN content_NN ._.
        
        
          Beta-glucuronidase_NNP binding_JJ assay_NN
          Binding_NNP of_IN β-glucuronidase_JJ was_VBD assayed_JJ as_IN described_VBN
          previously_RB [_NN 31_CD 32_CD ]_NN ._. Briefly_NNP ,_, cells_NNS were_VBD permeabilized_JJ
          with_IN 0_CD ._. 25_CD %_NN saponin_NN in_IN 50_CD mM_NN Hepes_NNP (_( pH_NN 7_CD ._. 0_CD )_) ,_, 150_CD mM_NN NaCl_NNP ,_,
          5_CD mM_NN β-glycerophosphate_JJ ,_, 0_CD ._. 5_CD %_NN human_JJ serum_NN albumin_NN ,_, and_CC 10_CD
          mM_NN mannose-_NN 6_CD -_: phosphate_NN (_( M_NNP 6_CD P_NN )_) for_IN 30_CD minutes_NNS on_IN ice_NN ._. The_DT
          cells_NNS were_VBD washed_VBN three_CD times_NNS with_IN ice-cold_JJ PBS_NNP
          containing_VBG 0_CD ._. 05_CD %_NN saponin_NN ._. They_PRP were_VBD incubated_JJ with_IN 20_CD ,_, 000_CD
          units_NNS /_NN ml_NN β-glucuronidase_JJ from_IN bovine_JJ liver_NN (_( Sigma_NNP )_) in_IN 50_CD
          mM_NN Hepes_NNP (_( pH_NN 7_CD ._. 5_LS )_) containing_VBG 150_CD mM_NN NaCl_NNP ,_, 5_CD mM_NN
          β-glycerophosphate_JJ ,_, 0_CD ._. 5_CD %_NN human_JJ serum_NN albumin_NN ,_, 0_CD ._. 5_CD %_NN
          saponin_NN with_IN or_CC without_IN 10_CD mM_NN M_NNP 6_CD P_NN overnight_JJ on_IN ice_NN ._. Cells_NNP
          were_VBD washed_VBN five_CD times_NNS with_IN ice-cold_JJ PBS_NNP containing_VBG 0_CD ._. 05_CD %_NN
          saponin_NN and_CC sonicated_JJ in_IN 100_CD mM_NN sodium_NN acetate_NN (_( pH_NN 4_CD ._. 6_CD )_) ._.
          The_DT protein_NN concentration_NN of_IN solubilized_JJ cell_NN extract_NN was_VBD
          measured_VBN and_CC enzyme_NN activity_NN was_VBD assayed_JJ as_IN follows_VBZ :_: for_IN
          each_DT reaction_NN 50_CD μl_NN cell_NN extract_NN were_VBD added_VBN to_TO 500_CD μl_NN of_IN
          100_CD mM_NN sodium_NN acetate_NN (_( pH_NN 4_CD ._. 0_CD )_) containing_VBG 1_CD mM_NN
          paranitrophenyl_NN (_( PNP_NNP )_) -_: β-glucuronide_JJ (_( Sigma_NNP )_) as_IN substrate_NN ._.
          After_IN an_DT incubation_NN period_NN of_IN 3_CD hours_NNS at_IN 37_CD °_NN C_NNP ,_, 500_CD μl_NN 1_CD M_NNP
          Na_NNP 
          2_CD CO_NNP 
          3_CD were_VBD added_VBN to_TO each_DT reaction_NN and_CC the_DT
          absorbance_NN was_VBD measured_VBN at_IN 400_CD nm_NN ._. Experimental_NNP values_NNS
          were_VBD compared_VBN to_TO a_DT standard_JJ curve_NN that_WDT was_VBD constructed_VBN
          using_VBG 1_CD -_: 100_CD nM_NN solutions_NNS of_IN PNP_NNP (_( Sigma_NNP )_) in_IN 500_CD μl_NN 100_CD mM_NN
          sodium_NN acetate_NN and_CC 500_CD μl_NN 1_CD M_NNP Na_NNP 
          2_CD CO_NNP 
          3_CD ._. Specific_JJ activity_NN was_VBD calculated_VBN
          as_IN nM_NN of_IN PNP_NNP produced_VBD /_NN hour_NN /_NN mg_NN of_IN protein_NN ._.
        
        
          Beta-glucuronidase_NNP endocytosis_NNS assay_NN
          Beta-glucuronidase_NNP endocytosis_NNS assay_NN was_VBD carried_VBN out_IN
          as_IN described_VBN previously_RB [_NN 33_CD ]_NN ._. Briefly_NNP ,_, confluent_NN cell_NN
          cultures_NNS were_VBD washed_VBN twice_RB with_IN pre-warmed_JJ serum-free_JJ
          DMEM_NNP followed_VBN by_IN incubation_NN with_IN DMEM_NNP containing_VBG 5_CD mg_NN /_NN ml_NN
          human_JJ serum_NN albumin_NN and_CC 10_CD mM_NN M_NNP 6_CD P_NN for_IN 20_CD minutes_NNS ._.
          Following_VBG incubation_NN cells_NNS were_VBD washed_VBN 3_CD times_NNS with_IN
          pre-warmed_JJ DMEM_NNP ._. Cells_NNP were_VBD then_RB incubated_JJ in_IN DMEM_NNP
          containing_VBG 5_CD mg_NN /_NN ml_NN human_JJ serum_NN albumin_NN alone_RB or_CC 4000_CD
          units_NNS β-glucuronidase_JJ with_IN or_CC without_IN 10_CD mM_NN M_NNP 6_CD P_NN for_IN 2_CD
          hours_NNS at_IN 37_CD °_NN C_NNP ._. Following_VBG the_DT incubation_NN ,_, the_DT cells_NNS were_VBD
          washed_VBN 5_CD times_NNS with_IN ice-cold_JJ PBS_NNP and_CC subjected_VBN to_TO enzyme_NN
          activity_NN assay_NN as_IN described_VBN above_IN ._.
        
        
          Cell_NNP proliferation_NN assay_NN (_( MTT_NNP assay_NN and_CC cell_NN
          counting_VBG )_)
          MCF-_NNP 7_CD cells_NNS were_VBD grown_VBN in_IN culture_NN plates_NNS (_( tissue_NN
          culture_NN grade_NN ,_, 12_CD wells_NNS ,_, flat_JJ bottom_NN )_) in_IN a_DT final_JJ volume_NN
          of_IN 1_CD ml_NN serum-containing_JJ culture_NN medium_NN per_IN well_RB ,_, in_IN a_DT
          humidified_JJ atmosphere_NN at_IN 37_CD °_NN C_NNP and_CC 5_CD %_NN CO_NNP 
          2_CD for_IN 3_CD days_NNS ._. After_IN infection_NN with_IN
          Ad-_NNP GFP_NNP /_NN IGF_NNP 2_CD R-R_NNP z_SYM or_CC Ad-_NNP GFP_NNP ,_, cells_NNS were_VBD incubated_JJ with_IN or_CC
          without_IN 50_CD ng_NN /_NN ml_NN IGF-II_NNP for_IN 4_CD days_NNS ._. 100_CD μl_NN MTT_NNP labelling_VBG
          reagent_NN were_VBD added_VBN to_TO each_DT well_RB and_CC incubated_JJ for_IN 4_CD hrs_NNS ,_,
          followed_VBN by_IN addition_NN of_IN 1_CD ml_NN solubilization_NN solution_NN into_IN
          each_DT well_RB ._. The_DT cells_NNS were_VBD incubated_JJ at_IN 37_CD °_NN C_NNP overnight_JJ ._.
          Spectrophotometrical_NNP absorbency_NN of_IN the_DT samples_NNS was_VBD
          measured_VBN using_VBG an_DT UV-visible_NNP Recording_NNP Spectrophotometer_NNP
          with_IN wavelength_NN of_IN 550_CD -_: 690_CD nm_NN ._. In_IN addition_NN ,_, the_DT total_JJ
          number_NN of_IN viable_JJ cells_NNS in_IN each_DT treatment_NN group_NN was_VBD
          counted_VBN by_IN a_DT trypan_NN blue_JJ exclusion_NN method_NN using_VBG a_DT
          hemocytometer_NN ._.
        
        
          Analysis_NNP of_IN cell_NN apoptosis_NNS
          MCF-_NNP 7_CD cells_NNS were_VBD infected_VBN with_IN Ad-_NNP GFP_NNP or_CC
          Ad-_NNP GFP_NNP /_NN Rz-_NNP IGF_NNP 2_CD R_NN ._. Seventy_CD two_CD hrs_NNS post_NN infection_NN ,_, cells_NNS
          were_VBD treated_VBN with_IN TNF_NNP (_( 0_CD ._. 1_LS ng_NN /_NN ml_NN )_) for_IN 24_CD hrs_NNS ._. Apoptotic_NNP
          cells_NNS were_VBD identified_VBN by_IN Hoechst_NNP staining_VBG using_VBG the_DT
          Vybrant_NNP ™_NN Apoptosis_NNP Kit_NNP #_# 5_CD (_( Molecular_NNP Probes_NNP )_) according_VBG to_TO
          the_DT manufacturer_NN 's_POS protocol_NN ._. In_IN addition_NN ,_, after_IN infection_NN
          with_IN Ad-_NNP GFP_NNP or_CC Ad-_NNP GFP_NNP /_NN Rz-_NNP IGF_NNP 2_CD R_NN and_CC treatment_NN with_IN TNF_NNP ,_,
          cell_NN viability_NN was_VBD assessed_VBN using_VBG the_DT MTT_NNP assay_NN Kit_NNP
          (_( Roche_NNP Molecular_NNP Biochemicals_NNP )_) and_CC cell_NN apoptosis_NNS was_VBD
          determined_VBN using_VBG the_DT Cell_NNP Death_NNP Detection_NNP ELISA_NNP Kit_NNP assay_NN
          (_( Roche_NNP Molecular_NNP Biochemicals_NNP )_) according_VBG to_TO the_DT
          manufacturer_NN 's_POS protocol_NN ._.
        
        
          Statistical_NNP analysis_NN
          Students_NNS 's_POS t-test_JJ was_VBD used_VBN to_TO evaluate_VB the_DT difference_NN
          between_IN two_CD values_NNS ._. Each_DT experiment_NN was_VBD repeated_VBN at_IN least_JJS
          three_CD times_NNS ._. Statistical_NNP significance_NN was_VBD accepted_VBN at_IN the_DT
          level_NN of_IN p_NN <_NN 0_CD ._. 05_CD ._.
        
      
      
        Results_NNS
        
          Cleavage_NNP reaction_NN of_IN the_DT ribozyme_NN in_IN vitro_NN
          The_DT M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN ribozyme_NN we_PRP constructed_VBN has_VBZ 13_CD -_: bp_NN
          binding_JJ arms_NNS complementary_JJ to_TO the_DT target_NN site_NN of_IN
          M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN mRNA_NN ,_, and_CC a_DT catalytic_JJ core_NN (_( Fig_NNP ._. 1_LS A_DT )_) ._. To_TO
          evaluate_VB the_DT bioactivity_NN /_NN specificity_NN of_IN the_DT ribozyme_NN and_CC
          the_DT accessibility_NN of_IN the_DT target_NN site_NN ,_, a_DT cleavage_NN reaction_NN
          
          in_IN vitro_NN was_VBD performed_VBN ._. The_DT
          substrates_NNS ,_, [_NN α-_NN 32_CD P_NN ]_NN labeled_VBD RNA_NNP transcripts_NNS containing_VBG
          45_CD bp_NN of_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN mRNA_NN or_CC an_DT unmatched_JJ sequence_NN ,_, were_VBD
          incubated_JJ with_IN the_DT ribozyme_NN as_IN described_VBN (_( see_VB Materials_NNPS
          and_CC Methods_NNP )_) ._. The_DT ribozyme_NN cleaved_JJ only_RB the_DT M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN
          mRNA_NN into_IN the_DT expected_VBN products_NNS ._. In_IN this_DT assay_NN ,_, the_DT
          hammerhead_NN ribozyme_NN was_VBD able_JJ to_TO cleave_NN about_IN 50_CD %_NN of_IN the_DT
          M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN target_NN within_IN 2_CD hr_NN of_IN incubation_NN ,_, and_CC by_IN 12_CD
          hrs_NNS ,_, more_JJR than_IN 90_CD %_NN of_IN the_DT M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN target_NN was_VBD converted_VBN
          to_TO the_DT expected_VBN products_NNS (_( Fig_NNP ._. 1_LS B_NNP )_) ._. These_DT results_NNS
          indicate_VBP a_DT high_JJ efficiency_NN and_CC specificity_NN of_IN the_DT
          ribozyme_NN 
          in_IN vitro_NN ._. 
        
        
          Expression_NNP of_IN the_DT M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R-_NNP ribozyme_NN in_IN cultured_JJ
          MCF-_NNP 7_CD cells_NNS
          To_TO test_VB whether_IN infection_NN of_IN cultured_JJ cells_NNS with_IN the_DT
          Ad-_NNP GFP_NNP /_NN Rz-_NNP IGF_NNP 2_CD R_NN can_MD induce_VB the_DT expression_NN of_IN the_DT ribozyme_NN
          (_( Rz-_NNP IGF_NNP 2_CD R_NN )_) ,_, total_JJ RNA_NNP was_VBD extracted_VBN from_IN cells_NNS infected_VBN
          with_IN Ad-_NNP GFP_NNP /_NN IGF_NNP 2_CD R-R_NNP z_SYM or_CC Ad-_NNP GFP_NNP ,_, and_CC subjected_VBN to_TO RT-PCR_NNP
          using_VBG ribozyme-specific_JJ primers_NNS ._. As_IN shown_VBN in_IN Fig_NNP ._. 2_LS ,_,
          infection_NN of_IN MCF-_NNP 7_CD cells_NNS with_IN Ad-_NNP GFP_NNP /_NN Rz-_NNP IGF_NNP 2_CD R_NN resulted_VBD in_IN
          positive_JJ expression_NN of_IN the_DT ribozyme_NN as_IN determined_VBN by_IN
          RT-PCR_NNP ._. As_IN expected_VBN ,_, the_DT ribozyme_NN sequence-specific_JJ
          primers_NNS produced_VBD a_DT 430_CD -_: bp_NN PCR_NNP fragment_NN only_RB in_IN cells_NNS
          infected_VBN with_IN Ad-_NNP GFP_NNP /_NN Rz-_NNP IGF_NNP 2_CD R_NN ,_, but_CC not_RB in_IN cell_NN infected_VBN
          with_IN the_DT control_NN viral_JJ vector_NN Ad-_NNP GFP_NNP ._.
        
        
          Ribozyme_NNP treatment_NN reduces_VBZ M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN expression_NN in_IN
          MCF-_NNP 7_CD cells_NNS
          To_TO examine_VB the_DT ability_NN of_IN the_DT ribozyme_NN to_TO reduce_VB
          levels_NNS of_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN mRNA_NN in_IN MCF-_NNP 7_CD cells_NNS ,_, total_JJ RNA_NNP was_VBD
          extracted_VBN from_IN cells_NNS infected_VBN with_IN Ad-_NNP GFP_NNP /_NN IGF_NNP 2_CD R-R_NNP z_SYM or_CC
          Ad-_NNP GFP_NNP ,_, and_CC subjected_VBN to_TO RT-PCR_NNP using_VBG M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R-_NNP specific_JJ
          primers_NNS ._. A_DT primer_NN specific_JJ for_IN human_JJ β-actin_JJ was_VBD added_VBN to_TO
          a_DT parallel_JJ reaction_NN to_TO serve_VB as_IN an_DT internal_JJ standard_NN ._.
          Cells_NNP were_VBD used_VBN 72_CD hrs_NNS post_NN infection_NN with_IN average_JJ
          infection_NN efficiency_NN of_IN 50_CD -_: 60_CD %_NN (_( for_IN which_WDT a_DT viral_JJ dose_NN
          used_VBN had_VBD minimal_JJ cytotoxicity_NN )_) ._. The_DT RT-PCR_NNP product_NN of_IN
          M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN was_VBD 730_CD bp_NN ,_, and_CC the_DT β-actin_JJ product_NN was_VBD 285_CD bp_NN ._.
          As_IN shown_VBN in_IN Fig_NNP ._. 3_LS ,_, the_DT Ad-_NNP GFP_NNP /_NN Rz-_NNP IGF_NNP 2_CD R-_NNP infected_JJ cells_NNS
          exhibit_NN a_DT significantly_RB lower_JJR level_NN of_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN mRNA_NN
          than_IN Ad-_NNP GFP-infected_NNP cells_NNS ,_, with_IN a_DT reduction_NN of_IN about_IN
          40_CD %_NN ._. There_EX was_VBD no_DT significant_JJ difference_NN in_IN the_DT level_NN of_IN
          M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN mRNA_NN between_IN Ad-_NNP GFP-infected_NNP cells_NNS and_CC
          uninfected_JJ cells_NNS (_( data_NNS not_RB shown_VBN )_) ;_: indicating_VBG that_DT
          infection_NN with_IN the_DT adenovirus_JJ itself_PRP did_VBD not_RB alter_VB the_DT
          endogenous_JJ M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN mRNA_NN level_NN ._. These_DT results_NNS
          demonstrate_VBP that_IN the_DT ribozyme_NN was_VBD highly_RB effective_JJ in_IN
          suppressing_VBG M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN expression_NN in_IN cultured_JJ MCF-_NNP 7_CD
          cells_NNS ._.
        
        
          Effect_NN of_IN ribozyme_NN expression_NN on_IN the_DT functional_JJ
          activity_NN of_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN
          To_TO determine_VB the_DT effect_NN of_IN the_DT ribozyme_NN on_IN the_DT
          functional_JJ activity_NN of_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN ,_, the_DT binding_JJ and_CC
          internalization_NN of_IN exogenous_JJ 125_CD I-IGF-II_NNP was_VBD measured_VBN in_IN
          cells_NNS infected_VBN with_IN Ad-_NNP GFP_NNP /_NN Rz-_NNP IGF_NNP 2_CD R_NN or_CC Ad-_NNP GFP_NNP ._. As_IN shown_VBN
          in_IN Fig_NNP ._. 4_LS A_DT ,_, cells_NNS infected_VBN with_IN Ad-_NNP GFP_NNP /_NN Rz-_NNP IGF_NNP 2_CD R_NN had_VBD a_DT
          corresponding_JJ reduction_NN of_IN ~_NN 40_CD %_NN in_IN 125_CD I-IGF-II_NNP
          internalization_NN when_WRB compared_VBN with_IN control_NN cells_NNS
          (_( infected_VBN with_IN Ad-_NNP GFP_NNP )_) ._. We_PRP also_RB examined_VBD the_DT effect_NN of_IN
          the_DT ribozyme_NN on_IN the_DT M_NNP 6_CD P-_NNP binding_JJ activity_NN of_IN the_DT M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN
          using_VBG the_DT M_NNP 6_CD P-_NNP bearing_NN lysosomal_NN enzyme_NN ,_, β-glucuronidase_JJ ,_,
          as_IN a_DT probe_NN ._. The_DT results_NNS showed_VBD that_IN the_DT maximal_NN
          M_NNP 6_CD P-_NNP binding_JJ capacity_NN of_IN MCF-_NNP 7_CD cells_NNS treated_VBN with_IN the_DT
          ribozyme_NN was_VBD about_IN 39_CD %_NN less_JJR than_IN that_DT of_IN controls_NNS (_( Fig_NNP ._.
          4_LS B_NNP )_) ._. Furthermore_RB ,_, we_PRP assessed_VBD the_DT ability_NN of_IN MCF-_NNP 7_CD cells_NNS
          to_TO internalize_NN exogenous_JJ β-glucuronidase_JJ after_IN treatment_NN
          with_IN ribozyme_NN ._. Similarly_RB ,_, the_DT M_NNP 6_CD P-_NNP inhibitable_JJ endocytosis_NNS
          of_IN β-glucuronidase_JJ by_IN ribozyme-treated_JJ MCF-_NNP 7_CD cells_NNS was_VBD
          about_IN 38_CD %_NN less_JJR than_IN that_DT of_IN control_NN cells_NNS (_( Fig_NNP ._. 4_LS C_NNP )_) ._.
          These_DT results_NNS confirm_VBP that_IN the_DT number_NN of_IN functional_JJ
          M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN in_IN ribozyme-treated_JJ cells_NNS was_VBD reduced_VBN ._.
        
        
          Effects_NNPS of_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R-_NNP ribozyme_NN expression_NN on_IN
          proliferation_NN of_IN MCF-_NNP 7_CD cells_NNS
          We_PRP examined_VBD the_DT effects_NNS of_IN ribozyme-induced_JJ M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN
          down-regulation_JJ on_IN the_DT growth_NN of_IN cultured_JJ MCF-_NNP 7_CD cells_NNS ._. We_PRP
          did_VBD not_RB observe_VB any_DT difference_NN in_IN cell_NN growth_NN between_IN
          GFP-only_NNP infected_JJ and_CC non-infected_JJ cells_NNS (_( data_NNS not_RB
          shown_VBN )_) ._. Thus_RB ,_, all_DT subsequent_JJ experiments_NNS were_VBD performed_VBN
          using_VBG GFP-only_NNP infected_JJ cells_NNS as_IN control_NN ._. Assessment_NNP of_IN
          cell_NN proliferative_JJ activity_NN by_IN MTT_NNP assay_NN and_CC counting_NN of_IN
          viable_JJ cells_NNS (_( data_NNS not_RB shown_VBN )_) indicated_VBD that_IN the_DT number_NN
          of_IN MCF-_NNP 7_CD cells_NNS in_IN ribozyme-expressing_JJ cultures_NNS was_VBD
          significantly_RB higher_JJR than_IN that_DT in_IN control_NN cultures_NNS (_( Fig_NNP ._.
          5_LS )_) ._. These_DT differences_NNS in_IN growth_NN pattern_NN and_CC cell_NN number_NN
          were_VBD even_RB more_RBR significant_JJ when_WRB the_DT cultures_NNS were_VBD treated_VBN
          with_IN exogenous_JJ IGF-II_NNP (_( 50_CD ng_NN /_NN ml_NN ,_, supplemented_JJ to_TO culture_NN
          medium_NN )_) (_( Fig_NNP ._. 5_LS )_) ._. These_DT results_NNS suggest_VBP that_IN decreasing_VBG
          M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN expression_NN by_IN the_DT ribozyme_NN can_MD enhance_VB
          proliferation_NN of_IN human_JJ breast_NN cancer_NN MCF-_NNP 7_CD cells_NNS via_IN an_DT
          IGF-II-related_NNP mechanism_NN ._.
        
        
          Effect_NN of_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R-_NNP ribozyme_NN expression_NN on_IN
          apoptosis_NNS of_IN MCF-_NNP 7_CD cells_NNS
          We_PRP examined_VBD the_DT effects_NNS of_IN ribozyme_NN expression_NN on_IN
          apoptosis_NNS of_IN cultured_JJ MCF-_NNP 7_CD cells_NNS ._. After_IN treatment_NN with_IN
          TNF_NNP ,_, as_IN shown_VBN in_IN Fig_NNP ._. 6_CD ,_, a_DT large_JJ number_NN of_IN control_NN cells_NNS
          underwent_VBD apoptosis_NNS ,_, as_IN indicated_VBN by_IN morphological_JJ
          changes_NNS (_( small_JJ round_NN shape_NN )_) and_CC bright_JJ blue_JJ nuclear_JJ
          staining_VBG ._. There_EX were_VBD significantly_RB more_RBR apoptotic_JJ cells_NNS
          in_IN control_NN cultures_NNS than_IN in_IN cultures_NNS expressing_VBG the_DT
          Ad-_NNP GFP_NNP /_NN IGF_NNP 2_CD R-R_NNP z_SYM ._. Accordingly_RB ,_, the_DT number_NN of_IN viable_JJ cells_NNS ,_,
          as_IN measured_VBN by_IN MTT_NNP analysis_NN ,_, in_IN cultures_NNS infected_VBN with_IN
          Ad-_NNP GFP_NNP /_NN IGF_NNP 2_CD R-R_NNP z_SYM was_VBD significantly_RB (_( about_IN 40_CD %_NN )_) higher_JJR than_IN
          in_IN cultures_NNS infected_VBN with_IN Ad-_NNP GFP_NNP (_( Fig_NNP ._. 7_CD A_DT )_) ._. The_DT number_NN of_IN
          apoptotic_JJ cells_NNS ,_, as_IN measured_VBN by_IN the_DT cell_NN death_NN ELISA_NNP
          assay_NN ,_, in_IN cultures_NNS infected_VBN with_IN Ad-_NNP GFP_NNP /_NN IGF_NNP 2_CD R-R_NNP z_SYM was_VBD
          significantly_RB (_( about_IN 36_CD %_NN )_) lower_JJR than_IN in_IN cultures_NNS infected_VBN
          with_IN Ad-_NNP GFP_NNP (_( Fig_NNP ._. 7_CD B_NNP )_) ._. These_DT results_NNS are_VBP consistent_JJ with_IN
          the_DT hypothesis_NNS that_IN decreasing_VBG M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN expression_NN by_IN
          ribozyme_NN treatment_NN can_MD reduce_VB cell_NN apoptosis_NNS ._.
        
      
      
        Discussion_NNP
        A_DT growing_VBG body_NN of_IN genetic_JJ evidence_NN suggests_VBZ that_IN the_DT
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD receptor_NN is_VBZ involved_VBN in_IN carcinogenesis_NNS [_NN 15_CD 16_CD 17_CD
        18_CD 19_CD 20_CD 21_CD 22_CD 23_CD 24_CD 25_CD 26_CD 27_CD 28_CD 29_CD ]_NN ._. However_RB ,_, direct_JJ
        evidence_NN of_IN a_DT growth-regulatory_JJ activity_NN for_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN is_VBZ
        lacking_VBG ._. In_IN this_DT study_NN ,_, using_VBG ribozyme_NN technology_NN ,_, we_PRP
        demonstrate_VBP an_DT association_NN of_IN decreased_VBD expression_NN and_CC
        function_NN of_IN the_DT M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN with_IN increased_VBN cell_NN proliferation_NN
        and_CC decreased_VBD susceptibility_NN to_TO TNF-induced_NNP apoptosis_NNS in_IN
        human_JJ breast_NN cancer_NN MCF-_NNP 7_CD cells_NNS ._. Expression_NNP of_IN the_DT ribozyme_NN
        targeted_VBN against_IN the_DT M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD receptor_NN in_IN MCF-_NNP 7_CD cells_NNS
        resulted_VBD in_IN down-regulation_JJ of_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN expression_NN ,_, as_IN
        measured_VBN by_IN RT-PCR_NNP ,_, and_CC M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN function_NN ,_, indicated_VBN by_IN a_DT
        decrease_NN in_IN internalization_NN of_IN 125_CD I-IGF-II_NNP ,_, and_CC
        β-glucuronidase_JJ binding_JJ and_CC endocytosis_NNS ._. Although_IN we_PRP have_VBP
        not_RB ruled_VBN out_RP a_DT RNAi_NNP effect_NN in_IN cells_NNS ,_, the_DT observed_VBD effects_NNS
        are_VBP likely_JJ the_DT consequence_NN of_IN the_DT specific_JJ cleavage_NN of_IN
        IGF_NNP 2_CD R_NN mRNA_NN by_IN the_DT ribozyme_NN we_PRP used_VBD ._.
        MTT_NNP analysis_NN and_CC viable_JJ cell_NN counts_VBZ showed_VBN that_IN
        ribozyme-mediated_JJ down-regulation_JJ of_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN also_RB
        resulted_VBD in_IN increased_VBN cell_NN proliferation_NN ._. Noticeably_NNP ,_, the_DT
        effect_NN of_IN ribozyme_NN expression_NN on_IN cell_NN growth_NN was_VBD more_RBR
        apparent_JJ in_IN the_DT presence_NN of_IN IGF-II_NNP ._. This_DT result_NN suggests_VBZ
        that_IN the_DT proliferative_JJ effect_NN of_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN down-regulation_JJ
        is_VBZ likely_JJ the_DT result_NN of_IN unchecked_JJ IGF-II_NNP stimulation_NN ._.
        Because_IN the_DT M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN is_VBZ believed_VBN to_TO sequester_VB and_CC degrade_NN
        IGF-II_NNP [_NN 10_CD ]_NN ,_, a_DT decrease_NN in_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN could_MD result_VB in_IN
        decreased_VBD degradation_NN and_CC hence_RB increased_VBN bioavailability_NN
        of_IN IGF-II_NNP to_TO the_DT IGF-I_NNP receptor_NN ,_, which_WDT mediates_NNS the_DT
        growth-promoting_JJ effect_NN of_IN IGF-II_NNP ._. Supporting_VBG evidence_NN for_IN
        the_DT involvement_NN of_IN IGF-II_NNP in_IN the_DT proliferative_JJ effect_NN
        resulting_VBG from_IN loss_NN of_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN function_NN comes_VBZ from_IN
        studies_NNS of_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN knock-out_JJ mice_NNS ._. M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R-_NNP null_NN mice_NNS
        display_VBP global_JJ hyperplasia_NN that_WDT coincides_VBZ with_IN elevated_VBD
        levels_NNS of_IN IGF-II_NNP ._. Most_JJS importantly_RB ,_, however_RB ,_, the_DT lethal_JJ
        nature_NN of_IN an_DT M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R-_NNP null_NN phenotype_NN is_VBZ reversed_VBN in_IN an_DT
        IGF-II-null_NNP background_NN [_NN 34_CD ]_NN ._. Although_IN we_PRP did_VBD not_RB measure_VB
        extracellular_NN levels_NNS of_IN IGF-II_NNP ,_, our_PRP$ results_NNS show_VBP that_IN
        ribozyme-mediated_JJ down-regulation_JJ of_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN leads_VBZ to_TO a_DT
        decrease_NN in_IN IGF-II_NNP internalization_NN ,_, supporting_VBG the_DT above_JJ
        possibility_NN ._.
        Our_PRP$ results_NNS also_RB showed_VBD that_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN down-regulation_JJ
        resulted_VBD in_IN decreased_VBD sensitivity_NN of_IN MCF-_NNP 7_CD cells_NNS to_TO
        TNF-induced_NNP apoptosis_NNS ._. Although_IN we_PRP do_VBP not_RB rule_VB out_RP the_DT
        potential_JJ contribution_NN of_IN the_DT IGF-II_NNP pathway_NN to_TO this_DT
        effect_NN ,_, we_PRP would_MD like_VB to_TO consider_VB other_JJ potential_JJ
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R-_NNP dependent_JJ mechanisms_NNS ,_, such_JJ as_IN lysosomal_NN proteases_NNS
        and_CC TGF-β_NNP signaling_VBG ,_, that_WDT may_MD directly_RB affect_VB cell_NN
        sensitivity_NN to_TO apoptosis_NNS ._. Recent_JJ evidence_NN suggests_VBZ that_IN
        lysosomal_NN enzymes_NNS ,_, such_JJ as_IN cathepsins_NNS B_NNP and_CC D_NNP contribute_VBP to_TO
        TNF-induced_NNP apoptosis_NNS 
        in_IN vitro_NN [_NN 35_CD 36_CD 37_CD 38_CD ]_NN and_CC 
        in_IN vivo_NN [_NN 39_CD ]_NN ._. The_DT M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD
        receptor_NN has_VBZ been_VBN shown_VBN to_TO be_VB involved_VBN in_IN binding_JJ ,_,
        transport_NN and_CC activation_NN of_IN lysosomal_NN enzymes_NNS ,_, including_VBG
        cathepsins_NNS [_NN 12_CD 13_CD ]_NN ._. Therefore_RB ,_, it_PRP is_VBZ possible_JJ that_IN
        down-regulation_JJ of_IN the_DT M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN results_NNS in_IN improper_JJ
        trafficking_NN and_CC activation_NN of_IN cathepsins_NNS ._. This_DT ,_, in_IN turn_NN
        would_MD eliminate_VB the_DT apoptotic_JJ cascades_NNS triggered_VBN by_IN these_DT
        enzymes_NNS under_IN TNF_NNP stimulation_NN and_CC result_NN in_IN decreased_VBD
        sensitivity_NN of_IN MCF-_NNP 7_CD cells_NNS to_TO apoptosis_NNS ._.
        It_PRP has_VBZ also_RB been_VBN shown_VBN that_IN TNF_NNP stimulation_NN involves_VBZ the_DT
        activation_NN of_IN TGF-β_NNP [_NN 40_CD 41_CD 42_CD ]_NN ,_, a_DT potent_JJ growth_NN
        inhibitor_NN for_IN many_JJ cell_NN types_NNS and_CC a_DT ligand_NN of_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN ._. In_IN
        fact_NN ,_, activation_NN of_IN TGF-β_NNP requires_VBZ the_DT binding_JJ of_IN latent_NN
        TGF-β_NNP to_TO the_DT M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD receptor_NN [_NN 11_CD ]_NN ._. Therefore_RB ,_,
        down-regulation_JJ of_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN expression_NN could_MD also_RB lead_VB to_TO
        a_DT decreased_VBN bioavailability_NN of_IN activated_VBN TGF-β_NNP ,_, thereby_RB
        decreasing_VBG the_DT sensitivity_NN of_IN MCF-_NNP 7_CD cells_NNS to_TO the_DT TGF-β_NNP
        apoptotic_JJ pathway_NN ._. A_DT detailed_VBN mechanism_NN of_IN the_DT observed_VBN
        effect_NN is_VBZ currently_RB under_IN investigation_NN ._.
      
      
        Conclusions_NNP
        Our_PRP$ findings_NNS that_IN ribozyme-mediated_JJ decrease_NN in_IN
        expression_NN and_CC functional_JJ activity_NN of_IN the_DT M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN result_NN
        in_IN a_DT growth_NN advantage_NN for_IN MCF-_NNP 7_CD cells_NNS indicate_VBP that_IN this_DT
        receptor_NN acts_NNS as_IN a_DT negative_JJ regulator_NN of_IN cell_NN growth_NN ._. This_DT
        is_VBZ consistent_JJ with_IN previous_JJ observations_NNS that_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN
        knockout_NN mice_NNS displayed_VBD generalized_JJ increased_VBN growth_NN and_CC
        cardiomygaly_RB (_( resulting_VBG from_IN cardiac_JJ myocyte_NN hyperplasia_NN )_) [_NN
        34_CD ]_NN ,_, and_CC that_IN antisense-mediated_JJ reduction_NN of_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN
        expression_NN enhances_VBZ tumorigenicity_NN in_IN JEG-_NNP 3_CD cells_NNS [_NN 43_CD ]_NN ._.
        Thus_RB ,_, loss_NN or_CC mutation_NN of_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN may_MD contribute_VB to_TO
        development_NN and_CC progression_NN of_IN tumors_NNS via_IN different_JJ
        pathways_NNS :_: by_IN increasing_VBG the_DT mitogenic_JJ activity_NN of_IN IGF-II_NNP
        and_CC decreasing_VBG the_DT apoptotic_JJ signaling_VBG of_IN TGF-β_NNP and_CC
        lysosomal_NN proteases_NNS ._. Further_RB studies_VBZ using_VBG various_JJ cell_NN
        types_NNS or_CC using_VBG animals_NNS are_VBP needed_VBN to_TO address_VB this_DT issue_NN ._.
        Ribozyme_NNP technology_NN ,_, as_IN we_PRP show_VBP here_RB ,_, is_VBZ a_DT useful_JJ tool_NN for_IN
        these_DT studies_NNS ._.
      
      
        Abbreviations_NNP
        Ad-_NNP GFP_NNP ,_, adenovirus_JJ carrying_NN GFP_NNP gene_NN ;_: Ad-_NNP GFP_NNP /_NN Rz-_NNP IGF_NNP 2_CD R_NN ,_,
        adenovirus_JJ carrying_NN both_DT ribozyme_NN against_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN and_CC GFP_NNP
        gene_NN ;_: GFP_NNP ,_, green_JJ fluorescent_NN protein_NN ;_: IGF-II_NNP ,_, insulin-like_JJ
        growth_NN factor_NN II_NNP ;_: M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN ,_, mannose_NN
        6_CD -_: phosphate_NN /_NN insulin-like_JJ growth_NN factor_NN II_NNP receptor_NN ;_: Rz_NNP ,_,
        ribozyme_NN ,_, TGF-β_NNP transforming_VBG growth_NN factor_NN beta_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Authors_NNP '_'' contributions_NNS
        ZC_NNP carried_VBD out_IN ribozyme_NN construction_NN and_CC functional_JJ
        assays_NNS ,_, YG_NNP carried_VBD out_IN virus_NN construction_NN ,_, infection_NN and_CC
        RT-PCR_NNP ,_, NL_NNP drafted_VBD the_DT manuscript_NN ,_, JXK_NNP conceived_VBD the_DT study_NN ,_,
        participated_VBD in_IN its_PRP$ design_NN and_CC coordination_NN ._. All_DT authors_NNS
        read_VBP and_CC approved_VBD the_DT manuscript_NN ._.
      
    
  
